DOJ Moves Medical Marijuana From Schedule I to III

Why It Matters

The Department of Justice moved marijuana policy in a meaningful direction on April 23, 2026, when Acting Attorney General Todd Blanche signed a final order rescheduling certain medical marijuana products under the Controlled Substances Act. The decision shifts FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III, a change that eases federal restrictions on medical use and research while leaving recreational marijuana untouched.

The action is partial and deliberate. It does not resolve the broader question of full marijuana rescheduling, and a new administrative hearing is already scheduled for June 29, 2026, to address that question. What it does do is mark the first formal federal acknowledgment, through binding regulatory action, that marijuana has accepted medical use.

The Big Picture

The rescheduling order fulfills a December 2025 Executive Order in which President Trump directed the DOJ to take "all necessary steps to expeditiously move marijuana from Schedule I to Schedule III." The April order was the direct result.

Schedule I is the most restrictive category under the Controlled Substances Act, reserved for substances with no accepted medical use and high abuse potential. Schedule III carries significantly fewer restrictions, making it easier for medical professionals to prescribe and for researchers to study a substance. The practical effect of moving state-licensed medical marijuana and FDA-approved products into Schedule III is a meaningful loosening of federal marijuana control for those specific categories.

Critically, the DOJ simultaneously withdrew a previous notice of hearing on a broader rulemaking and announced a new hearing beginning June 29, 2026. That signals the administration views this order as a first step, not a final answer.

The CRS report also addresses a question that has complicated cannabis policy discussions for years: international treaty obligations. Under the Single Convention on Narcotic Drugs, the U.S. carries drug control commitments that some have argued could be undermined by rescheduling. CRS assessed that "most of the Single Convention's obligations...will continue to be met by CSA statutory authorities and associated regulations," and that available controls "remain sufficient." That analysis gives the administration legal cover on the international front.

A separate but related development also shapes the landscape. In November 2025, Congress passed Pub. L. No. 119-37, amending the definition of hemp to be based on total THC concentration rather than solely delta-9 THC. That change affects which cannabis-derived products fall outside CSA controls entirely, adding another layer to an already complex regulatory picture.

Political Stakes

For the Administration

The order lets the Trump administration claim a concrete cannabis policy win without embracing full legalization. By limiting rescheduling to FDA-approved products and state-licensed medical marijuana, the White House threads a needle, appealing to voters who support medical access while maintaining a hard line on recreational use. The June 29 hearing keeps future options open.

For Republicans

Hardline conservatives who have opposed any loosening of federal marijuana enforcement will scrutinize whether the administration's incremental approach becomes a gateway to broader changes. The ongoing administrative hearing process gives critics a continued forum.

For Democrats

Many in the party have long pushed for descheduling marijuana entirely, not just rescheduling it. This action gives them partial credit for years of advocacy while also giving them room to argue the administration did not go far enough. The distinction between Schedule III and full descheduling will be a recurring talking point.

For the Public

Patients in states with qualifying medical marijuana programs stand to benefit most directly. The Schedule III designation makes it easier for medical research to proceed, which could eventually produce a stronger evidence base for or against various medical uses. For now, the change is largely regulatory, not a green light for broader access.

The Bottom Line

The DOJ's rescheduling of certain medical marijuana products is a consequential but carefully bounded action. It reflects a White House willing to move on cannabis policy in a measured way, with a second phase of rulemaking still ahead. Congress will need to watch whether the June 29 administrative hearing produces a push toward full rescheduling, and whether the November 2025 hemp definition change creates additional pressure for legislative clarification on cannabis-derived products more broadly.

Access the Legis1 platform for comprehensive political news, data, and insights.